Monitoring the antimicrobial susceptibility of Gramnegative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017)
Resumen: OBJECTIVE: Continuous antimicrobial resistance surveillance is recommended by Public Health authorities. We up-dated data from the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain.
METHODS: The antimicrobial susceptibility data and extended-spectrum beta-lactamase (ESBL) production in isolates recovered from intra-abdominal (IAI) (n=1,429) and urinary tract (UTI) (n=937) infections during the 2016- 2017 SMART study in 10 Spanish hospitals were analysed.
RESULTS: Escherichia coli was the most frequently microorganism isolated (48.3% and 53.7%) followed by Klebsiella spp. (11.5% and 21.9%) in IAIs and UTIs, respectively. Figures for Pseudomonas aeruginosa were 9.0% and 6.1%, being more frequently recovered from patients with nosocomial infections. Overall, 9.9% (IAI) and 14.0% (UTI) of E. coli, Klebsiella spp. and Proteus mirabilis isolates were ESBL-producers, being Klebsiella pneumoniae (34.5%) from UTI of nosocomial origin the most frequent. ESBL-producers were higher in patients >60 years in both IAIs and UTIs. As in previous years, amikacin (96.3%-100% susceptibility), ertapenem (84.2%-100%) and imipenem (70.3%- 100%) were the most active antimicrobials tested among Enterobacterales species. The activity of amoxicillin-clavulanic, piperacillin-tazobactam, and ciprofloxacin susceptibility was lower, particularly among ESBL-producers. Ertapenem susceptibility (88.9%-100%) was retained in ESBL-E. coli isolates that were resistant to these antimicrobials but decreased (28.6%-100%) in similar isolates of K. pneumoniae.
CONCLUSIONS: Continuous antimicrobial resistance surveillance from the SMART study reveals overall maintenance of ESBL-producers in Spain, although with higher presence in isolates from UTIs than from IAIs. Moreover, ertapenem activity was high in E. coli irrespective of ESBL production but decreased in K. pneumoniae, particularly among ESBL-producers.

Idioma: Inglés
Año: 2019
Publicado en: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 32, 2 (2019), 145-155
ISSN: 1988-9518

Originalmente disponible en: Texto completo de la revista

Factor impacto JCR: 1.132 (2019)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 246 / 270 = 0.911 (2019) - Q4 - T3
Categ. JCR: MICROBIOLOGY rank: 121 / 134 = 0.903 (2019) - Q4 - T3

Factor impacto SCIMAGO: 0.287 - Medicine (miscellaneous) (Q3) - Pharmacology (Q3) - Microbiology (medical) (Q3)

Tipo y forma: Article (Published version)
Área (Departamento): Área Microbiología (Dpto. Microb.Med.Pr.,Sal.Públ.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.

Exportado de SIDERAL (2020-07-16-09:32:26)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2019-05-23, last modified 2020-07-16

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)